



---

# Genomic and transcriptomic analysis of checkpoint blockade response in advanced non-small cell lung cancer

---

In the format provided by the authors and unedited

## **Supplementary Information**

### **Supplementary Figures**


Supplementary Figure 1. Significance analysis for SU2C-MARK cohort before and after sample exclusion. 2

### **Supplementary Notes**

Supplementary Note 1. Brief note on quality control following sample exclusion. 4

**Supplementary Figure 1. Significance analysis for SU2C-MARK cohort before and after sample exclusion.**

Comparison of  $-\log_{10}(\text{q-value})$  following False Discovery Rate (FDR) correction for all 106 features in the SU2C-MARK cohort before and after exclusion of RNA sample SU2CLC-DFC-DF0732. FDR q-values before and after exclusion are denoted as  $q_1$  and  $q_2$ , respectively. Features that retained significance following sample exclusion are displayed in orange, and features that remained non-significant are displayed in blue. No features transitioned between significant and non-significant categories.



### **Supplementary Note 1. Brief note on quality control following sample exclusion.**

Following re-annotation of one of our RNA-Seq samples (SU2CLC-DFC-DF0732) as a post-treatment rather than pre-treatment specimen, we compared the significance values of the feature list before and after exclusion of this specimen. As shown in **Supplementary Figure 1**, False Discovery Rate (FDR) q-values across the cohort were essentially unchanged, and no features transitioned from significant to non-significant or vice versa demonstrating the robustness of the analysis. Among the features, the largest impact was observed for “M2\_norm,” consistent with the fact that SU2CLC-DFC-DF0732 had high M2 signature activity.